GSK Reports P-III Trial (AReSVi-006) Results of Arexvy for Preventing Lower Respiratory Tract Disease Caused by Respiratory Syncytial Virus
Shots:
- The P-III trial evaluating the efficacy of a single dose of Arexvy in ~25,000 patients aged ≥60yrs. across 17 countries. Arexvy is expected to be available in the 2023-2024 RSV season
- The results showed that Arexvy was effective against RSV-LRTD & sev. LRTD over 2 full RSV seasons incl. in patients with underlying medical conditions. Against RSV-LRTD & sev. RSV-associated LRTD, vaccine efficacy during 1st season (82.6% & 94.1%); in mid-season (77.3% & 84.6%) after a median follow-up time of 14mos.; cumulative vaccine efficacy over 2 seasons after a median follow-up time of 18mos. was 67.2% & 78.8%
- For patients who received 2nd dose of Arexvy, cumulative vaccine efficacy over 2 seasons (67.1%) suggests revaccination after 12mos. does not provide additional benefits to the overall population
Ref: GSK | Image: GSK
Related News:- GSK’s Arexvy Receives EC’s Approval for the Prevention of Lower Respiratory Tract Disease in Individuals Aged ≥60 Years
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
